BioNTech Acquires MabVax Therapeutics? Antibody Assets to Expand Portfolio

MAINZ, Germany–(BUSINESS WIRE)–BioNTech SE, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today the acquisition of antibody assets and infrastructure from San Diego-based MabVax Therapeutics Holding, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company. Under the terms of the agreement, BioNTech has acquired MabVax Therapeutics? lead candidate, MVT-5873, as well as other p